May 2, 2022
Cellphire Therapeutics Names Anya Derbij, MD as Vice President of Clinical Operations
Dr. Derbij has worked for over 20 years in industry and joins the team as Vice President of Clinical Operations after successfully managing a pivotal trial in ophthalmic gene therapy during the worst of the COVID-19 pandemic.
March 31, 2022
Cellphire Therapeutics Treats First Patient in Phase 2/3 Cryopreserved Platelets Clinical Trial
Cellphire Therapeutics announced today that the 1st patient has been treated in its Phase 2/3 clinical trial, Randomized Controlled Trial Comparing Dimethyl Sulfoxide (DMSO) Cryopreserved Platelets to Liquid Stored Platelets in Patients Undergoing Cardiopulmonary Bypass Surgery (CRYPTICS).
February 8, 2022
Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors
Announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors.
January 12, 2022
Cellphire Therapeutics Appoints Roy A. Beveridge, M.D. to Scientific Advisory Board
Announced today the appointment of Roy A. Beveridge, M.D. to Scientific Advisory Board
December 20, 2021
Cellphire Therapeutics Names W. Allan Alexander, MD as Chief Medical Officer
Announced today the appointment of W. Allan Alexander, MD as the company’s Chief Medical Officer, effective immediately.
November 8, 2021
Cellphire Therapeutics Names Angie Howerton as Vice President of Finance, Controller and Treasurer
Ms. Howerton brings 25-years of progressive experience with a range of companies. Before joining Cellphire, she held leadership roles at ExeGi Pharma, Thermo Fisher Scientific, and MTI-GlobalStem.
May 28, 2021
Cellphire Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Thrombosomes in Bleeding Thrombocytopenic Patients
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that the first patient has been dosed in the company’s Phase 2 dose-ranging study of Thrombosomes®, a platelet-based freeze-dried hemostatic agent, in bleeding patients with thrombocytopenia. The study will evaluate the safety and efficacy of infusing multiple dose levels of Thrombosomes versus standard liquid stored platelets.
April 20, 2021
Cellphire Therapeutics Names Michael Gaffney as Company’s New CEO
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately. Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire. He will also join the Company’s board.